259 related articles for article (PubMed ID: 32745524)
1. Critical COVID-19 disease, homeostasis, and the "surprise" of effective glucocorticoid therapy.
Chrousos GP; Meduri GU
Clin Immunol; 2020 Oct; 219():108550. PubMed ID: 32745524
[No Abstract] [Full Text] [Related]
2. After 62 years of regulating immunity, dexamethasone meets COVID-19.
Cain DW; Cidlowski JA
Nat Rev Immunol; 2020 Oct; 20(10):587-588. PubMed ID: 32778829
[TBL] [Abstract][Full Text] [Related]
3. Treating COVID-19 with colchicine in community healthcare setting.
Della-Torre E; Della-Torre F; Kusanovic M; Scotti R; Ramirez GA; Dagna L; Tresoldi M
Clin Immunol; 2020 Aug; 217():108490. PubMed ID: 32492478
[No Abstract] [Full Text] [Related]
4. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
La Rosée F; Bremer HC; Gehrke I; Kehr A; Hochhaus A; Birndt S; Fellhauer M; Henkes M; Kumle B; Russo SG; La Rosée P
Leukemia; 2020 Jul; 34(7):1805-1815. PubMed ID: 32518419
[TBL] [Abstract][Full Text] [Related]
5. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
Omarjee L; Janin A; Perrot F; Laviolle B; Meilhac O; Mahe G
Clin Immunol; 2020 Jul; 216():108464. PubMed ID: 32405269
[No Abstract] [Full Text] [Related]
6. COVID-19 and Hypercoagulability.
Sholzberg M
Clin Adv Hematol Oncol; 2020 Jul; 18(7):386-389. PubMed ID: 32903249
[No Abstract] [Full Text] [Related]
7. Leukoerythroblastosis and plasmacytoid lymphocytes in a child with SARS-CoV-2-associated multisystem inflammatory syndrome.
Lee WS; Margolskee E
Blood; 2020 Aug; 136(7):914. PubMed ID: 32790856
[No Abstract] [Full Text] [Related]
8. Leukotrienes, a potential target for Covid-19.
Citron F; Perelli L; Deem AK; Genovese G; Viale A
Prostaglandins Leukot Essent Fatty Acids; 2020 Oct; 161():102174. PubMed ID: 32977289
[No Abstract] [Full Text] [Related]
9. Tissue damage from neutrophil-induced oxidative stress in COVID-19.
Laforge M; Elbim C; Frère C; Hémadi M; Massaad C; Nuss P; Benoliel JJ; Becker C
Nat Rev Immunol; 2020 Sep; 20(9):515-516. PubMed ID: 32728221
[TBL] [Abstract][Full Text] [Related]
10. Covid-19: Time for a paradigm change.
Buonaguro FM; Ascierto PA; Morse GD; Buonaguro L; Puzanov I; Tornesello ML; Bréchot C; Gallo RC
Rev Med Virol; 2020 Sep; 30(5):e2134. PubMed ID: 32618072
[No Abstract] [Full Text] [Related]
11. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
[TBL] [Abstract][Full Text] [Related]
12. Successful use of methylprednisolone for treating severe COVID-19.
Liu J; Zheng X; Huang Y; Shan H; Huang J
J Allergy Clin Immunol; 2020 Aug; 146(2):325-327. PubMed ID: 32479759
[No Abstract] [Full Text] [Related]
13. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis.
Mojtabavi H; Saghazadeh A; Rezaei N
Eur Cytokine Netw; 2020 Jun; 31(2):44-49. PubMed ID: 32933891
[TBL] [Abstract][Full Text] [Related]
14. Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm.
Mahmoudi S; Rezaei M; Mansouri N; Marjani M; Mansouri D
J Clin Immunol; 2020 Oct; 40(7):974-976. PubMed ID: 32648027
[No Abstract] [Full Text] [Related]
15. A plea for the pathogenic role of immune complexes in severe Covid-19.
Vuitton DA; Vuitton L; Seillès E; Galanaud P
Clin Immunol; 2020 Aug; 217():108493. PubMed ID: 32526273
[No Abstract] [Full Text] [Related]
16. Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19?
Menegazzi M; Campagnari R; Bertoldi M; Crupi R; Di Paola R; Cuzzocrea S
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708322
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19.
Moutsopoulos HM
Ann Rheum Dis; 2020 Sep; 79(9):1253-1254. PubMed ID: 32345616
[No Abstract] [Full Text] [Related]
18. Should we unstress SARS-CoV-2 infected cells?
Csukasi F; Rico G; Becerra J; Duran I
Cytokine Growth Factor Rev; 2020 Aug; 54():3-5. PubMed ID: 32563554
[No Abstract] [Full Text] [Related]
19. Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.
Manjaly Thomas ZR; Leuppi-Taegtmeyer A; Jamiolkowski D; Steveling-Klein E; Bellutti-Enders F; Scherer Hofmeier K; Hartmann K
J Allergy Clin Immunol; 2020 Oct; 146(4):786-789. PubMed ID: 32710973
[No Abstract] [Full Text] [Related]
20. Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment?
Costiniuk CT; Jenabian MA
Cytokine Growth Factor Rev; 2020 Jun; 53():63-65. PubMed ID: 32467020
[No Abstract] [Full Text] [Related]
[Next] [New Search]